Pruritus in Primary Sclerosing Cholangitis Without Dominant Biliary Stricture
Pruritus — sometimes severe and disabling — affects a substantial proportion of patients with primary sclerosing cholangitis (PSC). When a dominant or relevant biliary stricture or obstruction has been excluded, a distinct therapeutic pathway applies.
Clinical scenario: Primary sclerosing cholangitis presenting with pruritus (skin itching), in the absence of a dominant or relevant biliary stricture or biliary obstruction. Studies report pruritus in 30%–60% of PSC patients, ranging from mild to severely disabling. Once relevant biliary causes are ruled out, management follows a structured stepwise approach.
Treatment approach
When initial supportive measures are insufficient, second-line systemic pharmacological therapy is part of the structured approach — the full protocol specifies which agents apply, how they are sequenced, and at what point further escalation is considered.
References
DOI: 10.1002/hep.32771
- Many patients with PSC (30%–60%) suffer from pruritus, or itch, which can be severe and disabling.
- In the absence of a relevant stricture, a stepwise therapeutic approach should be followed starting with heat avoidance, emollients, and/or antihistamines, followed if necessary by first-line (cholestyramine), second-line (sertraline, rifampin, and/or naltrexone), and third-line (phenobarbital, plasmapheresis, and/or phototherapy) therapy, with LT considered for continued refractory symptoms.
- Second-line therapies for refractory symptoms include sertraline (100 mg/day), naltrexone (50–100 mg/daily), and rifampin (150–300 mg/day).
View source ↗